12 Best German Stocks to Buy According to Hedge Funds

Page 2 of 11

10. CureVac (NASDAQ:CVAC)

Number of Hedge Fund Holders: 6

CureVac (NASDAQ:CVAC) is a biopharmaceutical company that develops mRNA-based transformative medicines. It has a focus on prophylactic vaccines for infectious diseases and innovative cancer therapies. Its clinical pipeline includes vaccine candidates for COVID-19, rabies, and influenza, as well as mRNA-based cancer treatments.

The company is focused on its mRNA technology platform and its associated intellectual property, which is a key driver of its long-term value and potential revenue. The company is engaged in patent litigation to protect its foundational mRNA innovations. A recent development is the European Patent Office’s (EPO) decision to uphold the company’s European patent EP 3 708 668 B1 which describes its split poly-A tail technology, which enhances mRNA protein expression and medical efficacy.

Earlier in Q3 2024, the company saw a dramatic 2,897% year-over-year revenue increase to €493.9 million. This was driven by its collaboration with GSK which was focused on developing avian and seasonal influenza vaccines, as well as COVID-19 vaccines. A revised partnership with GSK, which included a €400 million upfront payment, extended CureVac’s (NASDAQ:CVAC) cash runway beyond 2028 and increased its total cash to €551 million.

Page 2 of 11